Literature DB >> 18230259

Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting.

M F Cotton1, H S Schaaf, G Lottering, H L Weber, J Coetzee, S Nachman.   

Abstract

Exposure to TB was quantified by screening human immunodeficiency virus (HIV) exposed infants aged 3-4 months for an isoniazid prophylaxis study where tuberculosis (TB) exposure excluded enrolment. Seventy-seven (10.1%, 95%CI 8.0-12.4) of 766 infants had contact with a TB source case. Nurses and lay counsellors identified 52 infants during pre-screening and doctors identified 25 during formal screening. High exposure may contribute to high rates of TB in HIV-exposed infants. Programs to prevent mother-to-child transmission of HIV offer an important opportunity to screen for TB. In-depth assessment is required for evaluating TB exposure.

Entities:  

Mesh:

Year:  2008        PMID: 18230259

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  34 in total

Review 1.  Childhood tuberculosis: epidemiology and natural history of disease.

Authors:  Ben J Marais
Journal:  Indian J Pediatr       Date:  2011-01-07       Impact factor: 1.967

2.  Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children.

Authors:  N Pavan Kumar; R Anuradha; R Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2011-09-28

3.  Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study.

Authors:  E R Maritz; G Montepiedra; L Liu; C D Mitchell; S A Madhi; R Bobat; A Violari; A Ogwu; A C Hesseling; M F Cotton
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

4.  Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.

Authors:  B Zeldow; S Kim; G McSherry; M F Cotton; P Jean-Philippe; A Violari; R Bobat; S Nachman; L M Mofenson; S A Madhi; C Mitchell
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

5.  Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.

Authors:  H Rabie; A Violari; T Duong; S A Madhi; D Josipovic; S Innes; E Dobbels; E Lazarus; R Panchia; A G Babiker; D M Gibb; M F Cotton
Journal:  Int J Tuberc Lung Dis       Date:  2011-09       Impact factor: 2.373

6.  Effects of cotrimoxazole prophylactic treatment on adverse health outcomes among HIV-exposed, uninfected infants.

Authors:  Anna Dow; Dumbani Kayira; Michael Hudgens; Annelies Van Rie; Caroline C King; Sascha Ellington; Athena Kourtis; Abigail Norris Turner; Steven Meshnick; Zebrone Kacheche; Denise J Jamieson; Charles Chasela; Charles van der Horst
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

7.  High Burden of Morbidity and Mortality but Not Growth Failure in Infants Exposed to but Uninfected with Human Immunodeficiency Virus in Tanzania.

Authors:  Lindsey M Locks; Karim P Manji; Roland Kupka; Enju Liu; Rodrick Kisenge; Christine M McDonald; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan
Journal:  J Pediatr       Date:  2016-11-07       Impact factor: 4.406

8.  A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.

Authors:  Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

9.  Circulating biomarkers of pulmonary and extrapulmonary tuberculosis in children.

Authors:  Nathella Pavan Kumar; R Anuradha; Bruno B Andrade; N Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2013-03-13

Review 10.  Tuberculosis in children.

Authors:  Ben J Marais; H Simon Schaaf
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-18       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.